Ginkgo Bioworks announced the extension of its multi‑year strategic partnership with Bayer, a collaboration that began in 2017 and focuses on advancing research and development of agricultural biologicals, including microbial nitrogen fixation.
Under the renewed agreement, Bayer retains the right to commercialize the resulting biological products as complementary to synthetic fertilizers. Ginkgo will support the partnership through its Agriculture Biologicals R&D site in West Sacramento, leveraging its Foundry and Codebase to accelerate discovery and optimization.
The extension follows successful milestones, including the integration of the Joyn Bio joint venture and the development of several candidate strains. Ginkgo’s Q3 2023 revenue was $55.43 million, with Cell Engineering revenue of $139 million and Biosecurity revenue of $108 million. The company revised its full‑year 2023 revenue guidance to $251 million, reflecting the impact of the partnership on its growth trajectory.
Management highlighted that the partnership strengthens Ginkgo’s position in the growing sustainable agriculture market, driven by rising fertilizer costs and demand for low‑carbon solutions. Dr. Mike Graham of Bayer Crop Science noted that biologicals are a key component of an integrated crop protection strategy.
The deal underscores Bayer’s commitment to biological solutions and Ginkgo’s platform capabilities, positioning both companies to capture market share in the expanding agricultural biologicals sector.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.